The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma (INHL) Who Have Progressed Following Treatment with Rituximab or a Rituximab-Containing Regimen in Mexico
作者
David Bertwistle,J. Munakata,Elizabeth Wehler,V. Leyva,Ana Valencia,A. Hernandez,La Torre,L. Gonzalez
出处
期刊:Value in Health [Elsevier BV] 日期:2013-10-22卷期号:16 (7): A411-A411被引量:1